![]() In March of this year, we presented results from our ongoing clinical trial of ATRC-101 demonstrating that anti-tumor activity is indeed associated with target expression, and we look forward to presenting additional clinical data later this year.” Our data align well with how different RNA-containing targets drive similar innate and adaptive immune responses elsewhere in human biology. “The preclinical data published in PNAS indicate that ATRC-101 activates myeloid cells of the innate immune system via an RNA-containing tumor target that we discovered via our platform, leading eventually to an adaptive immune response that attacks tumor, which is a novel mechanism of action for an oncology therapeutic. ![]() ![]() Serafini, Ph.D., Chief Strategy Officer of Atreca. "Immunotherapy approaches focusing on T cells have provided breakthroughs in treating solid tumors, but there remains an opportunity to drive anticancer immune responses via other immune cell types, particularly myeloid cells of the innate immune system,” said Tito A. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the peer-reviewed publication of preclinical data demonstrating how its lead product candidate, ATRC-101, activates the immune system and drives tumor destruction in a Proceedings of the National Academy of Sciences (PNAS) paper titled “ Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101.” SAN CARLOS, Calif., (GLOBE NEWSWIRE) - Atreca, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |